From: Targeting interleukin-1β and inflammation in lung cancer
Therapy | Target | Tumor type | Recruitment status | Study type | ClinicalTrials.gov identifier | Trial name | Start date | Estimated completion date |
---|---|---|---|---|---|---|---|---|
Canakinumab + pembrolizumab + chemotherapy | IL-1β + PD-1 | NSCLC | Active, not recruiting | Phase III | NCT03631199 [66] | CANOPY-1 | December 2018 | September 2022 |
Canakinumab + chemotherapy | IL-1β | NSCLC | Active, not recruiting | Phase III | NCT03626545 [67] | CANOPY-2 | January 2019 | March 2022 |
Canakinumab +/− pembrolizumab | IL-1β +/− PD-1 | NSCLC | Recruiting | Phase II | NCT03968419 [68] | CANOPY-N | November 2019 | January 2022 |
Canakinumab | IL-1β | NSCLC | Recruiting | Phase III | NCT03447769 [69] | CANOPY-A | March 2018 | January 2027 |
Canakinumab +/− PDR001 | IL-1β +/− PD-1 | NSCLC, TNBC, CRC | Active, not recruiting | Phase Ib | NCT02900664 [70] | – | August 2016 | March 2021 |
Canakinumab + PDR001 + chemotherapy | IL-1β +/− PD-1 | NSCLC | Active, not recruiting | Phase Ib | NCT03064854 [71] | ElevatION:NSCLC-101 | May 2017 | December 2021 |